Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.37 USD

18.37
769,549

+0.71 (4.02%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?

During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.

Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

ACADIA Surges on Early Success of Nuplazid Dementia Study

ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis.

Will ACADIA Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor ACADIA Pharmaceuticals.

ACADIA Enters Oversold Territory

ACADIA Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Top Ranked Momentum Stocks to Buy for August 29th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 29th

Top Ranked Momentum Stocks to Buy for August 26th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.

Top Ranked Momentum Stocks to Buy for August 23rd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 23rd.

Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment

Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.

Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

Top Ranked Momentum Stocks to Buy for August 15th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 15th.

Top Ranked Momentum Stocks to Buy for August 14th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 14th.

Top Ranked Momentum Stocks to Buy for August 12th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 12th.

ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc. (ACAD).

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 17.39% and 13.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.

Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?

Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.